BCL2 and neoplasm: Anti-tumor efficacy of Dox nanocarriers was compared with free Dox through qualitative analysis of pharmacodynamic markers (Bcl-2 and PARP; regulated by the apoptotic pathway), which showed little difference between the groups (Figure 5B).